Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
RESEARCH TRIANGLE PARK, N.C., March 29, 2017 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the 16th Annual Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 8:40 AM Eastern Time.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema, and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is a potential treatment for filoviruses. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitment development activities are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
